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The present case demonstrates a diffuse intense hepatic and, to a lesser degree, spleen, Tc-99m MDP uptake on a routine bone
scintigraphy resembling liver-spleen imaging.A 49-year-old femalewith a history of anaplastic plasma cell tumor and suffering from
bone pain was referred for bone scintigraphy to evaluate possible bone metastases. The bone scintigraphy showed diffuse hepatic
and spleen uptake of Tc-99m MDP resembling liver-spleen imaging. Furthermore, bone uptake of Tc-99m MDP was significantly
diminished and there were no abnormal foci throughout the skeleton. The bone scintigraphy of the present case of an anaplastic
plasma cell tumor suggests the possible presence of amyloidosis.
1. Introduction
Amyloidosis is characterized by an abnormal extracellu-
lar deposition of amyloid in various tissues and organs
of unknown cause [1, 2]. The pathogenesis of amyloid fibrils
is associated with amino acid replacements in prefibrillar
proteins and with protein instability [1]. Also, its clinical pre-
sentation, involving either single or multiple organs, results
in different signs and symptoms [2].
Depicting the presence of amyloid protein in the tis-
sue, mostly through invasive methods, is the primary way
of diagnosing amyloidosis [3]. We describe a 49-year-old
female with a history of anaplastic plasma cell tumor. Her
bone scintigraphy with Tc-99m MDP suggested the possible
presence of amyloidosis, by revealing intense diffuse tracer
uptake in the liver and spleen.
2. Case Report
A 49-year-old female was referred for a bone scintigraphy for
identification of possible bone metastasis. She complained of
general bone pain. Her past history included a lytic lesion in
the right mandible that had been treated with chemotherapy
and radiotherapy. Several investigations included bone mar-
row aspiration cytology and immunohistochemistry (IHC),
suggesting anaplastic plasma cell tumor. The serum elec-
trolyte, calcium, and phosphate levels were increased. The
serum creatinine level was also increased (Cr: 3.5mg/dL).
Ultrasonography revealed that the patient had a
mild splenomegaly. A bone scan revealed diffusely and
intensely hepatic 99Tc-MDP uptake, and to a lesser degree
in the spleen. Decreased skeletal uptake on bone scan
was also observed (Figure 1). We suggested the possibility of
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Figure 1: Anterior and posterior whole body bone scan, performed three hours after the intravenous administration of Tc-99mMDP, showed
diffuse and intense tracer uptake in the liver and, to a lesser degree, in the spleen, without any remarkable abnormal activity in the skeleton.
Decreased skeletal uptake was also observed.
immunoglobulin amyloidosis resulting from disturbed renal
function in the base of the patient’s underlying disease.
3. Discussion
Bone scintigraphy is frequently requested for identification of
possible bone metastasis in patients with a primary tumor,
even though it is generally indicated in multiple myeloma
through osteolytic lesions that depict no 99m Tc-MDP tracer
uptake [4]. A majority of such patients are referred for bone
scintigraphy because their presentation mimics metastatic
bone disease [4].
On the other hand, nonosseous uptake of bone-seeking
radiopharmaceuticals is observed in different conditions and
organs which are necessary to distinguish the pathophysio-
logical causes [5, 6].
The first explanation is that it is a mistake in radio-
pharmaceutical preparation and the formation of Tc-99m
colloid complex, resulting in abnormal distribution [7]. This
explanation is ruled out in this patient, because bone scans of
other patients were performed at the same time and did not
demonstrate such abnormality.
The other explanations for hepatic activity are hepatic
metastasis, necrosis, alcoholic liver disease, or history of
liver transplantation. The patient’s clinical manifestations,
ultrasound of the abdomen, and other investigationswere not
consistent with such explanations [8–11].
In addition, diffuse hepatic uptake, accompanied by
decreased skeletal uptake on bone scan, is normally noted
after an intravenous injection of iron colloid solutions or
methotrexate for treatment. The present case did not have
such a history [12, 13].
Furthermore, extraosseous uptake on bone scan is
observed in patients with renal failure as a result of a failure
to excrete the radiopharmaceuticals through the kidneys
[14]. Hypercalcemia and hyperparathyroidism resulting from
chronic renal failure cause soft tissue microcalcification [14].
Likewise, splenic uptake has been seen in the bone scan of
patientswith sickle-cell disease as a result of splenic infarction
and subsequent calcification [15]. Such explanations are not
congruent with the present case.
Furthermore, extraosseous uptake on bone scan has been
observed in amyloidosis [2]. Amyloidosis is characterized
by a heterogeneous group of disorders related to abnormal
extracellular protein deposits that can affect any organ and
can lead to end-organ dysfunction [16].
Five types of amyloidosis have been defined based on the
underlying disease: immunoglobulin amyloidosis, familial
amyloidosis, senile-systemic amyloidosis, secondary amyloi-
dosis, and hemodialysis-associated amyloidosis [2].
Few studies have suggested the use of scintigraphy as a
screening test for amyloidosis. Different radiopharmaceuti-
cals have been examined, including Ga-67 and Tc-99m sulfur
colloid, with mixed results [17, 18]. Bone radionuclides have
been shown to accumulate in different organs affected by
amyloidosis, including the liver, skin, skeletal muscle, and
myocardium [19, 20].
The precise mechanism by which bone-imaging radio-
pharmaceuticals accumulate within amyloids is not under-
stood [2]. The extracellular deposition of amyloids may
increase the local calcium level and subsequently enhance
the affinity for bone-seeking agents at the sites of amyloid
deposition. Nevertheless, when these radiopharmaceuticals
accumulate considerably in soft tissue, the presence of amy-
loid deposition should be considered [2].
Molecular imaging using radiolabeled positron emission
tomography (PET) tracers is now being employed for the
diagnosis of amyloid 𝛽 plaques in Alzheimer’s patients. Such
molecular imaging is currently into preclinical stages in
diagnosis of cardiac and peripheral amyloidosis [16, 21].
Amyloidosis is frequently related to decreased renal
function in patients with multiple myeloma, resulting from
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light chain deposition in various organs [14, 22]. In the
present case, a diagnosis of amyloidosis with diminished
renal function may provide an explanation for the abnormal
distribution of tracer in the liver and spleen, even though
histopathology was not preformed to confirm the presence
of amyloidosis. Extraosseous soft tissue and visceral accumu-
lation further raise the possibility of amyloidosis.The present
case suggests that further investigation and a directed biopsy
may be warranted.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] R. H. Falk, R. L. Comenzo, and M. Skinner, “The systemic
amyloidoses,”TheNew England Journal ofMedicine, vol. 337, no.
13, pp. 898–909, 1997.
[2] A. Fard-Esfehani and M. Assadi, “Myocardial Tc-99m MDP
uptake on the bone scintigraphy in the hemodialysis-associated
amyliodosis (an incidental finding),” Alasbimn Journal, vol. 8,
no. 30, pp. 30–37, 2005.
[3] J. D. Sipe, M. D. Benson, J. N. Buxbaum et al., “Amyloid
fibril protein nomenclature: 2010 recommendations from the
nomenclature committee of the International Society of Amy-
loidosis,” Amyloid, vol. 19, no. 4, pp. 167–170, 2012.
[4] R. C. F. Leonard, J. P. Owen, S. J. Proctor, and P. J. Hamilton,
“Multiple myeloma: radiology or bone scanning?” Clinical
Radiology, vol. 32, no. 3, pp. 291–295, 1981.
[5] A. Gentili, S. D.Miron, and E.M. Bellon, “Nonosseous accumu-
lation of bone-seeking radiopharmaceuticals,” Radiographics,
vol. 10, no. 5, pp. 871–881, 1990.
[6] A. Sood, R. K. Seam, S. Sethi, and M. Gupta, “Diffuse hepatic
and splenic Tc-99m MDP tracer uptake in case of multiple
myeloma,” Indian Journal of Nuclear Medicine, vol. 25, no. 2, pp.
70–72, 2010.
[7] J. MacDonald, “Idiopathic hepatic uptake of 99mTc methylene
diphosphonate: a case report,” Journal of Nuclear Medicine
Technology, vol. 29, no. 1, pp. 32–36, 2001.
[8] W.-J. Shih and J. Coupal, “Diffuse and intense Tc-99m HMDP
localization in the liver due to hypoxia secondary to respiratory
failure,” Clinical Nuclear Medicine, vol. 19, no. 2, pp. 116–120,
1994.
[9] E. Kawamura, J. Kawabe, T. Hayashi et al., “Splenic accumu-
lation of Tc-99m HMDP in a patient with severe alcoholic
cirrhosis of the liver,” Clinical Nuclear Medicine, vol. 30, no. 5,
pp. 351–352, 2005.
[10] S. J.Munoz, S. B. Nagelberg, P. J. Green et al., “Ectopic soft tissue
calciumdeposition following liver transplantation,”Hepatology,
vol. 8, no. 3, pp. 476–483, 1988.
[11] A. K. I˙lknur and U. I˙nci, “Diffuse hepatic uptake of Tc-99m
MDP on routine bone scan mimicking liver-spleen imaging:
disseminated liver metastases from the gastric Cancer,” Turkish
Journal of Nuclear Medicine, vol. 17, pp. 93–94, 2008.
[12] C. H. Park, H. S. Kim, H. Y. Shin, and H. C. Kim, “Hepatic
uptake of Tc-99mMDP on bone scintigraphy from intravenous
iron therapy (Blutal),” Clinical Nuclear Medicine, vol. 22, no. 11,
pp. 762–764, 1997.
[13] K. H. Lin, B. F. Shih, C. H. Tsao, and M. C. Wu, “Diffuse
liver uptake of technetium-99m-MDPbone scan due to hepato-
toxicity secondary to methotrexate therapy,” Annals of Nuclear
Medicine and Sciences, vol. 18, pp. 111–115, 2005.
[14] J. C. Evans, M. Murphy, and B. Eyes, “Extensive soft tissue
uptake of99Tcm methylene diphosphonate in a patient with
multiple myeloma,” British Journal of Radiology, vol. 73, no. 873,
pp. 1018–1020, 2000.
[15] W. Goy and W. J. Crowe, “Splenic accumulation of (99m)Tc
diphosphonate in a patient with sickle cell disease: case report,”
Journal of Nuclear Medicine, vol. 17, no. 2, pp. 108–109, 1976.
[16] W. Chen and V. Dilsizian, “Molecular imaging of amyloidosis:
will the heart be the next target after the brain?” Current
Cardiology Reports, vol. 14, no. 2, pp. 226–233, 2012.
[17] J. Banzo-Marraco, E. Nerin-Mora, and M. D. Abos-Olivares,
“Renal uptake of 67Ga-citrate in renal amyloidosis due to
familiar Mediterranean fever,” European Journal of Nuclear
Medicine, vol. 6, no. 6, pp. 277–280, 1981.
[18] A. D. Waxman, “Scintigraphic evaluation of diffuse hepatic
disease,” Seminars in Nuclear Medicine, vol. 12, no. 1, pp. 75–88,
1982.
[19] J.W.Moyle and S.M. Spies, “Bone scan in a case of amyloidosis,”
Clinical Nuclear Medicine, vol. 5, no. 2, pp. 51–52, 1980.
[20] S. Janssen, D. A. Piers, M. H. Van Rijswijk, S. Meijer, and E.
Mandema, “Soft-tissue uptake of 99mTc-diphosphonate and
99mTc-pyrophosphate in amyloidosis,” European Journal of
Nuclear Medicine, vol. 16, no. 8–10, pp. 663–670, 1990.
[21] J. S.Wall, T. Richey, A. Stuckey et al., “In vivomolecular imaging
of peripheral amyloidosis using heparin-binding peptides,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 108, no. 34, pp. E586–E594, 2011.
[22] F. Berk, H. Demir, A. Hacihanefioglu et al., “Hepatic and
splenic uptake of Tc-99mHDP inmultiplemyeloma: additional
findings on Tc-99m MIBI and Tc-99m sulfur colloid images,”
Annals of Nuclear Medicine, vol. 16, no. 2, pp. 137–141, 2002.
